Investment Stage

Focus Areas

About Investor

Graeme R. Martin, PhD is Chief Investment Officer at ALSA Ventures, a life-sciences-focused investment firm. He concentrates on early-stage and growth-stage therapeutics and biotech companies, often at the interface of drug discovery, development platforms, and novel modalities, with typical investments between $100K and $5M. His work spans seeding newco formations and backing more advanced clinical programs where specialist capital and scientific guidance are both critical. Martin has a background in pharmacology with a PhD from University College London and has held multiple leadership roles across biotech companies and venture-backed platforms in Europe and the US.